La procedura Replicel è basatta su una tecnologia di impianto cellule autologhe che replicano le cellule pilifere del paziente dai propri follicoli sani. Quando introdotto nelle aree con perdita di capelli, le cellule replicate iniziano una naturale rigenerazione dei capelli.
Replicel sarà sottoposto alla fase 1 dei trial clinici sull'uomo alla fine del 2010.
http://www.marketwatch.com/story/berkley-resources-purchases-interest-in-trichoscience-innovations-2010-09-20-1630560?reflink=MW_news_stmp
VANCOUVER, BRITISH COLUMBIA, Sep 20, 2010 (MARKETWIRE via COMTEX) -- Berkley Resources Inc. ()()() reports it has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company, has developed and patented a new hair cell replication technology called Replicel(TM) that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women. Berkley's share purchase represents 2.13% of TrichoScience's issued and outstanding share capital.
The Replicel(TM) procedure is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replicel(TM) will undergo Stage 1 Human Clinical Trials beginning in late 2010. For more information about TrichoScience and Replicel(TM) visit www.trichoscience.com.
E' in ritardo ma promette moooooooolto bene... ^^
Replicel sarà sottoposto alla fase 1 dei trial clinici sull'uomo alla fine del 2010.
http://www.marketwatch.com/story/berkley-resources-purchases-interest-in-trichoscience-innovations-2010-09-20-1630560?reflink=MW_news_stmp
VANCOUVER, BRITISH COLUMBIA, Sep 20, 2010 (MARKETWIRE via COMTEX) -- Berkley Resources Inc. ()()() reports it has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company, has developed and patented a new hair cell replication technology called Replicel(TM) that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women. Berkley's share purchase represents 2.13% of TrichoScience's issued and outstanding share capital.
The Replicel(TM) procedure is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replicel(TM) will undergo Stage 1 Human Clinical Trials beginning in late 2010. For more information about TrichoScience and Replicel(TM) visit www.trichoscience.com.
E' in ritardo ma promette moooooooolto bene... ^^